FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent

FDA action · OncLive · 2026-11-12. Number 5 in the UrologyWatch Top 5 for November 13, 2026.

FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.

Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.

Source: OncLive

The full November 13, 2026 edition · Today's urology news

Loading today's edition…